

# Helium in Ischemic Stroke.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Suspended
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON25537

### Source

Nationaal Trial Register

### Brief title

HIS

### Health condition

Helium, ischemic stroke.  
helium, ischemische beroerte.

## Sponsors and support

### Primary sponsor:

Tergooiziekenhuizen  
Rijksstraatweg 1, 1261 AN Blaricum,  
The Netherlands.

Phone: +31 35 539 11 11

### Source(s) of monetary or material Support:

Tergooiziekenhuizen  
Rijksstraatweg 1, 1261 AN Blaricum,  
The Netherlands.

Phone: +31 35 539 11 11

## Intervention

## Outcome measures

### Primary outcome

1. Main safety endpoint: Clinical deterioration, defined as a decrease on the Glasgow Coma Scale of more than 2 points and/or a decrease of 4 or more points on the NIHSS;
2. Primary clinical endpoint: Comparison of the change in neurological deficits, quantified by the National Institute of Health Stroke Scale (NIHSS) during helium therapy.

### **Secondary outcome**

1. Safety endpoint: Death by any cause and total and specific serious adverse events, including symptomatic heamorrhagic transformation or intracranial heamorrhage;
2. Secondary clinical endpoints: Neurological deficits at 4 hours, 24 hours, 1 week and at 3 months, quantified on NIHSS and the level of dependency measures on the modified Rankin Scale (mRS) at three months.

## **Study description**

### **Background summary**

In the treatment of acute cerebral ischemia the aim is to preserve and salvage the penumbra and to protect the brain from reperfusion injury. Recently, helium was shown to provide neuroprotection in an experimental setting of cerebral ischemia-reperfusion. Substantial evidence of organ protection by noble gases exists in the field of cardioprotection. In the absence of evidence of neuroprotection by helium in human, further investigation is necessary. Our aim is to investigate the safety and feasibility of helium administration in patients with acute ischemic stroke, not eligible for thrombolysis.

### **Study objective**

Primary objective: Is 4 hours of inhalation of a gaseous mixture of 79% helium and 21% oxygen feasible and save in acute ischemic stroke?

### **Study design**

T0: Start of helium breathing for 4 hours;

T1= 4 hours: Clinical evaluation using the NIHSS and VAS-score;

T2= 24hours: Clinical evaluation using NIHSS;

T3= 1 week: Clinical evaluation using NIHSS;

T4= 3 months: Clinical evaluation using NIHSS and mRS.

## Intervention

Helium breathing through a mask during 4 hours in the intervention group compared to normal air in control group.

## Contacts

### Public

Rijksstraatweg 1  
J.R. Kruijk, de  
Blaricum 1261 AN  
The Netherlands  
+31 (0)35 5391111

### Scientific

Rijksstraatweg 1  
J.R. Kruijk, de  
Blaricum 1261 AN  
The Netherlands  
+31 (0)35 5391111

## Eligibility criteria

### Inclusion criteria

1. Age  $\geq 18$  years, not eligible for rt-PA;
2. Clinical anterior circulation ischemic stroke diagnosed by an independent physician;
3.  $< 12$  hours of witnessed symptom onset;
4. NIHSS  $\geq 4$ ;
5. Pre-admission mRS  $\leq 1$ ;
6. Visual estimation of penumbra/infarct ratio  $> 20\%$  on Ct-perfusion;
7. Informed consent.

## Exclusion criteria

1. Eligible for rt-PA thrombolysis;
2. Inability to obtain written informed consent;
3. Legal incapacity;
4. Medically unstable (blood pressure > 230/120 or <100/60mmHg, pulse > 120 bpm, body temperature > 39C);
5. Intracerebral haemorrhage on admission non-enhanced CT;
6. Rapidly improving neurological deficits;
7. Pregnancy;
8. Impaired renal function (serum creatinin levels > 130micromol/L);
9. Allergic to contrast agent;
10. Use of anticoagulation drugs or coagulopathy (PTT > 1.5 times control);
11. Use of following nephrotoxic mediactions: aminoglycosids, amfoterine B or cisplatin;
12. Contra-indication or intolerance to any substance;
13. Saturation on admission of < 90%.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	Active

## Recruitment

NL  
Recruitment status: Suspended  
Start date (anticipated): 01-01-2010  
Enrollment: 20  
Type: Anticipated

## Ethics review

Positive opinion  
Date: 19-02-2010  
Application type: First submission

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 33571  
Bron: ToetsingOnline  
Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL2114
NTR-old	NTR2231
CCMO	NL21743.003.08
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON33571

## Study results

## **Summary results**

N/A